Closomers of High Boron Content:  Synthesis, Characterization, and Potential Application as Unimolecular Nanoparticle Delivery Vehicles for Boron Neutron Capture Therapy

2006 ◽  
Vol 45 (1) ◽  
pp. 278-285 ◽  
Author(s):  
Ling Ma ◽  
Julie Hamdi ◽  
Francis Wong ◽  
M. Frederick Hawthorne
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Potential Application ◽  
Boron Content ◽  
Neutron Capture Therapy ◽  
Nanoparticle Delivery ◽  
Boron Neutron Capture ◽  
High Boron ◽  
Delivery Vehicles

scholarly journals High Boron-loaded DNA-Oligomers as Potential Boron Neutron Capture Therapy and Antisense Oligonucleotide Dual-Action Anticancer Agents

Molecules ◽  
2017 ◽  
Vol 22 (9) ◽  
pp. 1393 ◽  
Author(s):  
Damian Kaniowski ◽  
Katarzyna Ebenryter-Olbińska ◽  
Milena Sobczak ◽  
Błażej Wojtczak ◽  
Sławomir Janczak ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antisense Oligonucleotide ◽  
Neutron Capture Therapy ◽  
Dna Oligomers ◽  
Boron Neutron Capture ◽  
Dual Action ◽  
High Boron

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Sign in / Sign up

Export Citation Format

Share Document